ICER finds opioid use disorder treatments not cost-effective

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines.

The institute compared the clinical effectiveness and value of three buprenorphine products and a naltrexone product against drugs such as Suboxone buprenorphine/naltrexone sublingual film and methadone using a broad

Read the full 540 word article

User Sign In